Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) shares were up 0.6% during mid-day trading on Wednesday . The company traded as high as $5.20 and last traded at $5.19. Approximately 460,305 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 1,020,780 shares. The stock had previously closed at $5.16.

A number of research analysts have recently issued reports on AUPH shares. Leerink Swann lifted their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. HC Wainwright restated a “buy” rating and issued a $12.00 price objective (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a research report on Monday, October 30th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, January 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, October 23rd. Finally, BidaskClub cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.79.

The firm has a market cap of $433.30, a PE ratio of -4.27 and a beta of 2.38.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. The business’s revenue was up .0% on a year-over-year basis. sell-side analysts predict that Aurinia Pharmaceuticals Inc will post -1.08 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its holdings in Aurinia Pharmaceuticals by 1.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock worth $502,000 after acquiring an additional 931 shares during the period. Royal Bank of Canada grew its holdings in Aurinia Pharmaceuticals by 8.6% during the 2nd quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,341 shares during the period. Cutler Capital Management LLC grew its holdings in Aurinia Pharmaceuticals by 33.3% during the 3rd quarter. Cutler Capital Management LLC now owns 40,000 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 10,000 shares during the period. Alyeska Investment Group L.P. grew its holdings in Aurinia Pharmaceuticals by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock worth $4,273,000 after acquiring an additional 12,171 shares during the period. Finally, FMR LLC grew its holdings in Aurinia Pharmaceuticals by 0.3% during the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock worth $35,969,000 after acquiring an additional 19,200 shares during the period. 28.08% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/02/08/aurinia-pharmaceuticals-auph-trading-up-0-6.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.